| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AO1 MEDICATION COMPLIANCE TO STATIN THERAPY AND ITS IMPACT ON DISEASE OUTCOMES IN TYPE 2 DIABETES
|
Zhang, L
|
|
2007
|
10 |
Supplement 2 |
p. A6-
1 p.
|
artikel
|
| 2 |
AO3 PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO A 1.5-2 TIMES INCREASED CHANCE OF BLOOD PRESSURE GOAL ATTAINMENT IN STAGE 2 ANTIHYPERTENSIVE PATIENTS
|
Breekveldt-Postma, NS
|
|
2007
|
10 |
Supplement 2 |
p. A7-
1 p.
|
artikel
|
| 3 |
Assessing Differences in Utility Scores: A Comparison of Four Widely Used Preference-Based Instruments
|
Wee, Hwee-Lin
|
|
2007
|
10 |
Supplement 2 |
p. 256-265
10 p.
|
artikel
|
| 4 |
Assessing Differences in Utility Scores: A Comparison of Four Widely Used Preference-Based Instruments
|
Wee, Hwee-Lin
|
|
2007
|
10 |
Supplement 2 |
p. 256-265
|
artikel
|
| 5 |
Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death: A Cost or an Investment?
|
Boriani, Giuseppe
|
|
2007
|
10 |
Supplement 2 |
p. 1-2
2 p.
|
artikel
|
| 6 |
Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death: A Cost or an Investment?
|
Boriani, Giuseppe
|
|
2007
|
10 |
Supplement 2 |
p. 1-2
|
artikel
|
| 7 |
CASE 2 COST CONTROL FOR MENTAL HEALTH
|
Dubberly, J
|
|
2007
|
10 |
Supplement 2 |
p. A197-A198
nvt p.
|
artikel
|
| 8 |
Cost-Benefit Analysis of Preventing Sudden Cardiac Deaths with an Implantable Cardioverter Defibrillator versus Amiodarone
|
Caro, J. Jaime
|
|
2007
|
10 |
Supplement 2 |
p. 13-22
|
artikel
|
| 9 |
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
|
Thompson, David
|
|
2007
|
10 |
Supplement 2 |
p. 367-376
10 p.
|
artikel
|
| 10 |
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
|
Thompson, David
|
|
2007
|
10 |
Supplement 2 |
p. 367-376
|
artikel
|
| 11 |
CV3 DO DIFFERENCES IN DOSE IMPACT ADHERENCE TO SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS 2-PILL AMLODIPINE AND ATORVASTATIN?
|
Tang, SSK
|
|
2007
|
10 |
Supplement 2 |
p. A221-A222
nvt p.
|
artikel
|
| 12 |
DB3 CLINICAL AND PATIENT REPORTED OUTCOMES OVER THE FIRST 6 MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM: DATA FROMTHE INSTIGATE STUDY
|
Timlin, L
|
|
2007
|
10 |
Supplement 2 |
p. A232-
1 p.
|
artikel
|
| 13 |
DB1 IMPACT OF ROSIGLITAZONETHERAPY ONTHE LIPID PROFILE AND LIPID-LOWERINGTREATMENT IN TYPE 2 DIABETES PATIENTS
|
Suh, DC
|
|
2007
|
10 |
Supplement 2 |
p. A231-
1 p.
|
artikel
|
| 14 |
DB2 RACIAL DIFFERENCES IN EMERGENCY ROOM VISITS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES
|
Shenolikar, R
|
|
2007
|
10 |
Supplement 2 |
p. A17-
1 p.
|
artikel
|
| 15 |
DB4 TREATMENT ADHERENCE AND BARRIERS TO ADHERENCE ARE ASSOCIATED WITH GLYCEMIC CONTROL AND EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE
|
Alvarez-Guisasola, F
|
|
2007
|
10 |
Supplement 2 |
p. A232-
1 p.
|
artikel
|
| 16 |
Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis: The ESPRINT Questionnaire
|
Valero, Antonio
|
|
2007
|
10 |
Supplement 2 |
p. 466-477
12 p.
|
artikel
|
| 17 |
Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis: The ESPRINT Questionnaire
|
|
|
2007
|
10 |
Supplement 2 |
p. 466-477
|
artikel
|
| 18 |
Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney Cancer
|
Cella, David
|
|
2007
|
10 |
Supplement 2 |
p. 285-293
9 p.
|
artikel
|
| 19 |
Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney Cancer
|
Cella, David
|
|
2007
|
10 |
Supplement 2 |
p. 285-293
|
artikel
|
| 20 |
Diabetes Cost Model of a Hospital in Thailand
|
Riewpaiboon, Arthorn
|
|
2007
|
10 |
Supplement 2 |
p. 223-230
8 p.
|
artikel
|
| 21 |
Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand
|
Teerawattananon, Yot
|
|
2007
|
10 |
Supplement 2 |
p. 61-72
12 p.
|
artikel
|
| 22 |
Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand
|
Teerawattananon, Yot
|
|
2007
|
10 |
Supplement 2 |
p. 61-72
|
artikel
|
| 23 |
Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study
|
Bracco, Andrea
|
|
2007
|
10 |
Supplement 2 |
p. 238-246
|
artikel
|
| 24 |
ED3 DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITHTYPE 2 DIABETES IN GERMANY AND UNITED KINGDOM: DATA FROMTHE INSTIGATE STUDY
|
Timlin, L
|
|
2007
|
10 |
Supplement 2 |
p. A223-
1 p.
|
artikel
|
| 25 |
ED2 LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN INTYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING
|
Goodall, G
|
|
2007
|
10 |
Supplement 2 |
p. A222-A223
nvt p.
|
artikel
|
| 26 |
ED4 THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA
|
McEwan, P
|
|
2007
|
10 |
Supplement 2 |
p. A223-
1 p.
|
artikel
|
| 27 |
ES3 COST-EFFECTIVENESS OF FIRST EYE CATARACT SURGERY IN ELDERLY WOMEN: A RANDOMISED CONTROLLED TRIAL
|
Sach, TH
|
|
2007
|
10 |
Supplement 2 |
p. A348-
1 p.
|
artikel
|
| 28 |
ES5 DOES ARTHROSCOPIC ACROMIOPLASTY PROVIDE ANY ADDITIONAL VALUE IN THE TREATMENT OF SHOULDER IMPINGEMENT SYNDROME? ATWO-YEAR RANDOMIZED CONTROLLED TRIAL
|
Ketola, S
|
|
2007
|
10 |
Supplement 2 |
p. A238-
1 p.
|
artikel
|
| 29 |
ES2/PMH44 COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA
|
Leeuwenkamp, O
|
|
2007
|
10 |
Supplement 2 |
p. A301-
1 p.
|
artikel
|
| 30 |
HP3 ASSESSING THE IMPACT OF A NATIONAL DRUG BENEFIT PROGRAM ONTHE USE OF GENERIC DRUGS AND DIFFERENT THERAPEUTIC CLASSES
|
Zhang, JX
|
|
2007
|
10 |
Supplement 2 |
p. A234-A235
nvt p.
|
artikel
|
| 31 |
MC2 BAYESIAN MODELING OF RESOURCE USE ALONGSIDE MULTINATIONAL RANDOMISED CLINICAL TRIALS
|
Gauthier, A
|
|
2007
|
10 |
Supplement 2 |
p. A224-
1 p.
|
artikel
|
| 32 |
MD4 MEDICAID PREFERRED DRUG LISTS' COSTS TO PHYSICIANS
|
Ketcham, JD
|
|
2007
|
10 |
Supplement 2 |
p. A4-A5
nvt p.
|
artikel
|
| 33 |
MH3 PREVALENCE OF LIVER DISEASES IN MEDICAID RECIPIENTS WITH SCHIZOPHRENIA
|
Wu, JH
|
|
2007
|
10 |
Supplement 2 |
p. A14-A15
nvt p.
|
artikel
|
| 34 |
NE2 IMPACT OF PATIENT COMORBIDITIES ON PHARMACOLOGICAL TREATMENT OF INSOMNIA:AN ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY DATA: 1995-2004
|
Pawaskar, MD
|
|
2007
|
10 |
Supplement 2 |
p. A9-
1 p.
|
artikel
|
| 35 |
OB4 THE RELATIONSHIP BETWEEN OBESITY AND HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS OR RHEUMATOID ARTHRITIS
|
Eisenberg, DF
|
|
2007
|
10 |
Supplement 2 |
p. A20-
1 p.
|
artikel
|
| 36 |
PAA10 ADULT ASTHMA: A COHORT ANALYSIS OF USE AND COST OF HOSPITAL AND EMERGENCY DEPARTMENT CARE BY LOCATION OF RESIDENCE OVERTWELVE MONTHS
|
O'Brien, JA
|
|
2007
|
10 |
Supplement 2 |
p. A400-A401
nvt p.
|
artikel
|
| 37 |
PAA22 CAN PATIENTS WITH ASTHMA FEEL THEIR MAINTENANCE INHALER WORKING RIGHT AWAY? REPRODUCIBILITY AND VALIDITY OF A WEEKLY DIARY FOR ASSESSING PERCEPTION AND SATISFACTION
|
Leidy, N
|
|
2007
|
10 |
Supplement 2 |
p. A115-
1 p.
|
artikel
|
| 38 |
PAA25 IMPACT OF ALLERGIC RHINITIS ON WORK PRODUCTIVITY
|
Beyer, A
|
|
2007
|
10 |
Supplement 2 |
p. A116-
1 p.
|
artikel
|
| 39 |
PAA7 PHARMACOECONOMIC OUTCOMES OF LEVALBUTEROL AND RACEMIC ALBUTEROL IN HOSPITALIZED PATIENTS REQUIRING NEBULIZATION THERAPY (POLARIS)
|
Claus, R
|
|
2007
|
10 |
Supplement 2 |
p. A110-A111
nvt p.
|
artikel
|
| 40 |
PAR6 A COST EFFECTIVENESS PRELIMINARY STUDY ON A NEW TOTAL KNEE ARTHROPLASTY SYSTEM AND A PERIPHERAL NERVE BLOCKADETECHNIQUE
|
Aguiar García, F
|
|
2007
|
10 |
Supplement 2 |
p. A244-A245
nvt p.
|
artikel
|
| 41 |
PAR20 ASSOCIATION BETWEEN DOSE CHANGES AND HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTSWHO RECEIVED INFLIXIMAB THERAPY
|
Nair, KV
|
|
2007
|
10 |
Supplement 2 |
p. A249-
1 p.
|
artikel
|
| 42 |
PAR3 COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS IN ARGENTINA
|
Solé, JP
|
|
2007
|
10 |
Supplement 2 |
p. A243-A244
nvt p.
|
artikel
|
| 43 |
PAR2 DOES RACE INFLUENCE A PATIENT'S LIKELIHOOD OF BEING PRESCRIBED SELECTIVE CYCLOOXYGENASE-2 INHIBITORS (COX-2S) VERSUS OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS) IN MEDICAID MANAGED CARE PLANS (MCOS)?
|
Neild, A
|
|
2007
|
10 |
Supplement 2 |
p. A243-
1 p.
|
artikel
|
| 44 |
PAR9 IMPACT OF PATIENT'S OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS
|
Gleeson, M
|
|
2007
|
10 |
Supplement 2 |
p. A119-A120
nvt p.
|
artikel
|
| 45 |
PCASE6 CLINICAL OUTCOMES ASSESSMENT IN BEHAVIORAL HEALTH CARE: SEARCHING FOR PRACTICAL SOLUTIONS
|
Madan, A
|
|
2007
|
10 |
Supplement 2 |
p. A203-
1 p.
|
artikel
|
| 46 |
PCN53 A COMPARISION OF THE PSYCHOMETRICS PROPERTIES OF HEALTH RELATED QUALITY OF LIFE INSTRUMENTS USED IN GLIOBLASTOMA MULTIFORME PATIENTS
|
Walthour, AE
|
|
2007
|
10 |
Supplement 2 |
p. A140-
1 p.
|
artikel
|
| 47 |
PCN8 A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA): THE ITALIAN CASE
|
Esposito, G
|
|
2007
|
10 |
Supplement 2 |
p. A324-
1 p.
|
artikel
|
| 48 |
PCN4 BUDGET IMPACT ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING
|
Orlewska, E
|
|
2007
|
10 |
Supplement 2 |
p. A124-
1 p.
|
artikel
|
| 49 |
PCN18 BURDEN OF ILLNESS ANALYSIS OF MALIGNANT METASTATIC MELANOMA IN THE UNITED STATES
|
Thompson, D
|
|
2007
|
10 |
Supplement 2 |
p. A128-
1 p.
|
artikel
|
| 50 |
PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN
|
Chao, TY
|
|
2007
|
10 |
Supplement 2 |
p. A327-
1 p.
|
artikel
|
| 51 |
PCN17 COST-EFFECTIVENESS ANALYSIS OFTRASTUZUMAB THERAPY IN PATIENTS WITH EARLY HER-2 POSITIVE BREAST CANCER IN BRAZIL
|
Correa, M
|
|
2007
|
10 |
Supplement 2 |
p. A327-
1 p.
|
artikel
|
| 52 |
PCN49 COST-UTILITY ANALYSIS OF MAINTENANCE THERAPY WITH RITUXIMAB FOR FOLLICULAR LYMPHOMA IN BRAZIL
|
Chiattone, CS
|
|
2007
|
10 |
Supplement 2 |
p. A337-A338
nvt p.
|
artikel
|
| 53 |
PCN66 DEFINING HEALTH STATE UTILITIES FOR HAND-FOOT-SYNDROME
|
Roth, S
|
|
2007
|
10 |
Supplement 2 |
p. A343-
1 p.
|
artikel
|
| 54 |
PCN21 DRUG UTILIZATION, COST CONSIDERATIONS AND TRANSFUSION PATTERNS FOR ERYTHROPOIETIC STIMULATING AGENTS IN A MANAGED CARE CANCER POPULATION
|
Gosselin, A
|
|
2007
|
10 |
Supplement 2 |
p. A129-
1 p.
|
artikel
|
| 55 |
PCN28 ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2-3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER: A FINNISH PERSPECTIVE
|
Fàrkkilà, N
|
|
2007
|
10 |
Supplement 2 |
p. A331-
1 p.
|
artikel
|
| 56 |
PCN52 GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY
|
Boncz, I
|
|
2007
|
10 |
Supplement 2 |
p. A338-
1 p.
|
artikel
|
| 57 |
PCN36 NEW SYSTEM OF COSTLY DRUG REIMBURSEMENT IN FRANCE:ASSESSMENT IN A TEACHING HOSPITAL ONCOLOGY DEPARTMENT
|
Baylatry, MT
|
|
2007
|
10 |
Supplement 2 |
p. A134-
1 p.
|
artikel
|
| 58 |
PCN25 PHARMACOECONOMIC EVALUATION OF CAPECITABINE (XELODA) FOR GASTRIC CANCER IN THE UNITED KINGDOM
|
Cowell, W
|
|
2007
|
10 |
Supplement 2 |
p. A330-
1 p.
|
artikel
|
| 59 |
PCN39 THE COST OF TREATING AND MANAGING ABNORMAL CERVICAL CONDITIONS IN IRELAND
|
Rash, B
|
|
2007
|
10 |
Supplement 2 |
p. A334-
1 p.
|
artikel
|
| 60 |
PCV1 AN OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF ROSUVASTATIN IN PATIENTS WITH DIABETES IN GENERAL PRACTICE ACROSS THE UNITED KINGDOM
|
Kassianos, G
|
|
2007
|
10 |
Supplement 2 |
p. A405-
1 p.
|
artikel
|
| 61 |
PCV92 ATTITUDES AND BELIEFS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK, ABOUT HYPERCHOLESTEROLEMIA AND ITS TREATMENT IN SPAIN. THE PRACTICE STUDY
|
Caloto, MT
|
|
2007
|
10 |
Supplement 2 |
p. A434-
1 p.
|
artikel
|
| 62 |
PCV49 BUDGET IMPACT AND MEDICAL RESOURCES USED TO CONTROL BLEEDS IN PATIENTS HOSPITALIZED DUE TO ACUTE CORONARY SYNDROME (ACS)
|
Guijarro, P
|
|
2007
|
10 |
Supplement 2 |
p. A420-
1 p.
|
artikel
|
| 63 |
PCV66 COMPARING QUALITY OF CARE: IS IT MEANINGFUL?
|
Witt, JC
|
|
2007
|
10 |
Supplement 2 |
p. A426-
1 p.
|
artikel
|
| 64 |
PCV32 COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION, TYPE-2 DIABETES AND RENAL DAMAGE IN MEXICO
|
Hernandez, H
|
|
2007
|
10 |
Supplement 2 |
p. A415-
1 p.
|
artikel
|
| 65 |
PCV4 CUMULATIVE PERSISTENCE OF ANTIHYPERTENSIVE MEDICATION AS A NEWLY PRESCRIBED DRUG IN A MEDICAID POPULATION
|
Gu, A
|
|
2007
|
10 |
Supplement 2 |
p. A37-
1 p.
|
artikel
|
| 66 |
PCV85 DOES A SINGLE PILL COMBINING AMLODIPINE AND ATORVASTATIN OFFER GREATER LONG-TERM ADHERENCE BENEFIT OVER LOW-COST GENERIC 2-PILL CALCIUM CHANNEL BLOCKER/STATIN REGIMENS?
|
Patel, BV
|
|
2007
|
10 |
Supplement 2 |
p. A432-
1 p.
|
artikel
|
| 67 |
PCV18 ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF EXPLANTED ORGANS IN HEART TRANSPLANTATION
|
Kalo, Z
|
|
2007
|
10 |
Supplement 2 |
p. A410-A411
nvt p.
|
artikel
|
| 68 |
PCV21 ECONOMIC EVALUATION OF EPLERENONE COMPARED WITH PLACEBO IN PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND HEART FAILURE IN MEXICO
|
Mould-Quevedo, J
|
|
2007
|
10 |
Supplement 2 |
p. A42-A43
nvt p.
|
artikel
|
| 69 |
PCV63 ESTIMATING A SOUTH AFRICAN PHARMACOECONOMIC THRESHOLD FOR PHARMACEUTICAL DECISION MAKING
|
Steyn, R
|
|
2007
|
10 |
Supplement 2 |
p. A425-
1 p.
|
artikel
|
| 70 |
PCV64 FACTOR SCREENING FOR PARSIMONY OF VARIABLES IN PHARMACOECONOMIC MODELS
|
Klein, RW
|
|
2007
|
10 |
Supplement 2 |
p. A55-
1 p.
|
artikel
|
| 71 |
PCV35 IMPACT OF NESIRITIDE ON TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF): EVIDENCE FROM A US HOSPITAL DATABASE
|
DiDomenico, R
|
|
2007
|
10 |
Supplement 2 |
p. A47-
1 p.
|
artikel
|
| 72 |
PCV80 PERSISTENCE AND ADHERENCE TO HYPOLIPEMIC THERAPY IN REAL PRACTICE: RESULTS OF A LARGE ADMINISTRATIVE DATABASE
|
Mantovani, LG
|
|
2007
|
10 |
Supplement 2 |
p. A430-A431
nvt p.
|
artikel
|
| 73 |
PCV54 PROJECTED COST SAVINGS COMPARISON TO MANAGED CARE ORGANIZATIONS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN THE US
|
Gandhi, PK
|
|
2007
|
10 |
Supplement 2 |
p. A52-
1 p.
|
artikel
|
| 74 |
PCV7 RELATIONSHIPS BETWEEN VENOUS THROMBOEMBOLIC (VTE) PROPHYLACTIC TREATMENTS AND VTE COMPLICATIONS OR THROMBOCYTOPENIA AND AMONG VETERANS RECEIVING TOTAL HIP REPLACEMENTS
|
Raisch, DW
|
|
2007
|
10 |
Supplement 2 |
p. A38-
1 p.
|
artikel
|
| 75 |
PCV38 TREATMENT OF DEPRESSION IN CORONARY ARTERY DISEASE:A STUDY OF NATIONAL AMBULATORY MEDICAL CARE VISITS FROM 2000 TO 2004
|
Sankaranarayanan, J
|
|
2007
|
10 |
Supplement 2 |
p. A48-
1 p.
|
artikel
|
| 76 |
PCV35 USE OF DRUG-ELUTING STENTS IN THE THERAPY AND PREVENTION OF RESTENOSIS: AN ECONOMIC EVALUATION FOR THE SICILY REGIONAL GOVERNMENT IN ITALY
|
Colombo, GL
|
|
2007
|
10 |
Supplement 2 |
p. A416-
1 p.
|
artikel
|
| 77 |
PDB7 ADDITION OF INHALED HUMAN INSULIN AS AN OPTION FOR PATIENTS WITHTYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETICS SHOULD AVOID COMPLICATIONS PREDICTED BY EAGLE MODEL
|
Littlewood, K
|
|
2007
|
10 |
Supplement 2 |
p. A255-
1 p.
|
artikel
|
| 78 |
PDB57 ADMINISTRATIVE CLAIMS ANALYSIS OF NEW EXENATIDE PATIENTS WITH TYPE 2 DIABETES
|
Fabunmi, R
|
|
2007
|
10 |
Supplement 2 |
p. A272-
1 p.
|
artikel
|
| 79 |
PDB53 AN EVALUATION OF TREATMENT DISCONTINUATION PATTERNS IN PEOPLE WITH TYPE I AND TYPE 2 DIABETES SWITCHED TO ALTERNATIVE SHORT ACTING INSULIN REGIMENS IN UK GENERAL PRACTICE
|
Currie, CJ
|
|
2007
|
10 |
Supplement 2 |
p. A270-
1 p.
|
artikel
|
| 80 |
PDB2 A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) PATIENTS WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) AS ADD-ONTHERAPY
|
Fon, F
|
|
2007
|
10 |
Supplement 2 |
p. A254-
1 p.
|
artikel
|
| 81 |
PDB4 A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) IN MONOTHERAPY
|
Celaya, JM
|
|
2007
|
10 |
Supplement 2 |
p. A254-
1 p.
|
artikel
|
| 82 |
PDB10 A PHARMACOECONOMIC EVALUATION FOR THE TREATMENT OF MEXICAN PATIENTS WITH DIABETES TYPE 2
|
Contreras-Hernandez, I
|
|
2007
|
10 |
Supplement 2 |
p. A62-
1 p.
|
artikel
|
| 83 |
PDB48 A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES
|
Colclough, HA
|
|
2007
|
10 |
Supplement 2 |
p. A269-
1 p.
|
artikel
|
| 84 |
PDB58 CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES
|
Misurski, D
|
|
2007
|
10 |
Supplement 2 |
p. A272-
1 p.
|
artikel
|
| 85 |
PDB43 COMPARATIVE STUDY OF ANNUAL TREATMENT COSTS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
|
Alvarez Guisasola, F
|
|
2007
|
10 |
Supplement 2 |
p. A267-
1 p.
|
artikel
|
| 86 |
PDB3 COMPARING EFFICIENCY OF INSULIN GLARGINE VS. NPH INSULIN IN PATIENTS WITHTYPE 2 DIABETES
|
Kodela, B
|
|
2007
|
10 |
Supplement 2 |
p. A254-
1 p.
|
artikel
|
| 87 |
PDB20 COMPARISON OF ROSIGLITAZONE VERSUS PIOGLITAZONE INTRODUCTION AND ASSOCIATED HEALTH CARE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES
|
Balkrishnan, R
|
|
2007
|
10 |
Supplement 2 |
p. A65-
1 p.
|
artikel
|
| 88 |
PDB78 COMPARISONS BETWEEN ITEQAND DTSQ IN A SAMPLE OF TYPE 2 DIABETES MELLITUS PATIENTS
|
Moock, J
|
|
2007
|
10 |
Supplement 2 |
p. A278-A279
nvt p.
|
artikel
|
| 89 |
PDB13 COPAYMENT LEVEL AND MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS MANAGED WITH INSULIN ASPART PEN THERAPY
|
Lee, WC
|
|
2007
|
10 |
Supplement 2 |
p. A63-
1 p.
|
artikel
|
| 90 |
PDB28 COST-EFFECTIVENESS ANALYSIS OF ACARBOSE IN THE PREVENTION OFTYPE 2 DIABETES IN SOUTH KOREA
|
JongMann, K
|
|
2007
|
10 |
Supplement 2 |
p. A262-
1 p.
|
artikel
|
| 91 |
PDB23 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN A POLISH SETTING
|
Aristides, M
|
|
2007
|
10 |
Supplement 2 |
p. A261-
1 p.
|
artikel
|
| 92 |
PDB27 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN CHINA
|
Lynch, M
|
|
2007
|
10 |
Supplement 2 |
p. A262-
1 p.
|
artikel
|
| 93 |
PDB33 COST EFFECTIVENESS OF JANUVIA VERSUS AVANDIA AS SUPPLEMENTARY TREATMENT IN COMBINATION WITH METFORMIN FOR PATIENTS WITHTYPE 2 DIABETES
|
Verheggen, BG
|
|
2007
|
10 |
Supplement 2 |
p. A264-
1 p.
|
artikel
|
| 94 |
PDB21 COST-EFFECTIVENESS OF STRICT “GET TO GOAL” TREATMENT DIRECTIVES IN THE TREATMENT OFYOUNGER PATIENTS WITH NEWLY DIAGNOSEDTYPE 2 DIABETES MELLITUS (T2DM)
|
Willis, M
|
|
2007
|
10 |
Supplement 2 |
p. A260-
1 p.
|
artikel
|
| 95 |
PDB38 COST OF ILLNESS STUDY OFTYPE-2 DIABETES IN COLOMBIA
|
Einarson, TR
|
|
2007
|
10 |
Supplement 2 |
p. A265-A266
nvt p.
|
artikel
|
| 96 |
PDB42 COSTS ASSOCIATED WITH THE FIRST SIX MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM: DATA FROM THE INSTIGATE STUDY
|
Timlin, L
|
|
2007
|
10 |
Supplement 2 |
p. A267-
1 p.
|
artikel
|
| 97 |
PDB6 DATABASE ASSESSMENT OFTHE EFFECTIVENESS OF BRAND VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITHTYPE 2 DIABETES MELLITUS
|
Katzir, I
|
|
2007
|
10 |
Supplement 2 |
p. A255-
1 p.
|
artikel
|
| 98 |
PDB17 DETERMINATION OF HEALTH CARE COSTS INCURRED BY SWEDISH PATIENTS WITH TYPE 2 DIABETES
|
Ringborg, A
|
|
2007
|
10 |
Supplement 2 |
p. A64-
1 p.
|
artikel
|
| 99 |
PDB36 DIFFERENCES IN EQ-5D SCORES FOR US AND UK-BASED PREFERENCE SCORING SYSTEMS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS
|
Sundaram, M
|
|
2007
|
10 |
Supplement 2 |
p. A70-A71
nvt p.
|
artikel
|
| 100 |
PDB51 DRUG USE FOR DIABETES MELLITUSTYPE 2 AND ITS COMPLICATIONS IN SLOVAKIA
|
Ilavska, A
|
|
2007
|
10 |
Supplement 2 |
p. A270-
1 p.
|
artikel
|
| 101 |
PDB35 ECONOMIC ANALYSIS OFTHE TREATMENT WITH INSULIN GLARGINE PLUS ORAL ANTIDIABETICS (BOT) COMPARED TO TWICE DAILY PREMIXED INSULIN (CT) BASED ONTHE LAPTOPTRIAL
|
Janka, HU
|
|
2007
|
10 |
Supplement 2 |
p. A264-A265
nvt p.
|
artikel
|
| 102 |
PDB14 ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN PEN THERAPY IN MEDICAID TYPE 2 DIABETES PATIENTS: A RETROSPECTIVE DATABASE ANALYSIS
|
Pawaskar, MD
|
|
2007
|
10 |
Supplement 2 |
p. A63-
1 p.
|
artikel
|
| 103 |
PDB34 EFFECT OF INSULIN GLARGINE AND NPH INSULIN ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
Gupta, KS
|
|
2007
|
10 |
Supplement 2 |
p. A70-
1 p.
|
artikel
|
| 104 |
PDB72 EMPIRIC PSYCHOLOGICAL TYPING OF PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED ORALLY, AND CORRESPONDING GLYCAEMIC CONTROL/RESULTS FROM THE SETT2D SURVEY
|
Stridde, E
|
|
2007
|
10 |
Supplement 2 |
p. A277-
1 p.
|
artikel
|
| 105 |
PDB49 ESTIMATE OF HEALTH CARE RESOURCES NEEDED TO INITIATE INSULIN—RELATIVE COSTS OF DIFFERENT OPTIONS IN UK CLINICAL PRACTICE
|
McKendrick, J
|
|
2007
|
10 |
Supplement 2 |
p. A269-
1 p.
|
artikel
|
| 106 |
PDB63 ESTIMATING THE LONG-TERM CLINICAL OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN ASPART (NOVORAPID®) FROM HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE POLISH SETTING
|
Erny-Albrecht, K
|
|
2007
|
10 |
Supplement 2 |
p. A274-
1 p.
|
artikel
|
| 107 |
PDB30 EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OFTYPE 2 DIABETES IN A SPANISH SETTING
|
Tucker, D
|
|
2007
|
10 |
Supplement 2 |
p. A263-
1 p.
|
artikel
|
| 108 |
PDB32 EVALUATING THE LONG-TERM CLINICAL AND ECONOMIC IMPLICATIONS OF CONVERTING TYPE 2 DIABETES PATIENTS TO INSULIN DETEMIR (±ORAL HYPOGLYCEMIC AGENTS) FROM INSULIN GLARGINE BASED REGIMENS IN GERMANY; DATA FROMTHE PREDICTIVE STUDY
|
Valentine, WJ
|
|
2007
|
10 |
Supplement 2 |
p. A263-A264
nvt p.
|
artikel
|
| 109 |
PDB22 EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITHTYPE 2 DIABETES IN SPAIN AND ITALY
|
Erny-Albrecht, K
|
|
2007
|
10 |
Supplement 2 |
p. A260-
1 p.
|
artikel
|
| 110 |
PDB8 EVALUATION OF THE ASSOCIATION BETWEEN GLUCOSE VARIABILITY, AS MEASURED BY THE DIFFERENCE BETWEEN MAXIMUM AND MINIMUM, INTERMITTENT, RANDOM BLOOD GLUCOSE OBSERVATIONS, AND LONGTERM CLINICAL OUTCOME IN SUBJECTS WITHTYPE 2 DIABETES TREATED WITH INSULIN
|
Poole, C
|
|
2007
|
10 |
Supplement 2 |
p. A255-A256
nvt p.
|
artikel
|
| 111 |
PDB54 FACTORS ASSOCIATED WITH CONTINUED CLINICAL INERTIA AMONG PATIENTS WITH TYPE 2 DIABETES
|
Lafata, JE
|
|
2007
|
10 |
Supplement 2 |
p. A271-
1 p.
|
artikel
|
| 112 |
PDB1 GLYCEMIC CONTROL GOAL ATTAINMENT AMONGTYPE 2 DIABETIC PATIENTSWHO INITIATED ORAL COMBINATION THERAPY IN HUNGARY
|
György, B
|
|
2007
|
10 |
Supplement 2 |
p. A253-
1 p.
|
artikel
|
| 113 |
PDB32 HEALTH-RELATED QUALITY OF LIFE AND UTILITIES OF RESPONDENTS WITH TYPE 2 DIABETES COMPARED TO THOSE WITH DIFFERING LEVELS OF CARDIOMETABOLIC RISK
|
Chapman, RH
|
|
2007
|
10 |
Supplement 2 |
p. A69-
1 p.
|
artikel
|
| 114 |
PDB31 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PRIMARY CARE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DEPRESSION
|
Shah, BM
|
|
2007
|
10 |
Supplement 2 |
p. A69-
1 p.
|
artikel
|
| 115 |
PDB30 HEALTH RELATED QUALITY OF LIFE ON BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES IN THE GENERAL ADULT POPULATION IN ENGLAND
|
Christensen, T
|
|
2007
|
10 |
Supplement 2 |
p. A68-A69
nvt p.
|
artikel
|
| 116 |
PDB25 HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS: RELATIONSHIPS IN A CROSS-SECTIONAL STUDY
|
Sundaram, M
|
|
2007
|
10 |
Supplement 2 |
p. A67-
1 p.
|
artikel
|
| 117 |
PDB39 IMPACT OF HBAIC IN TYPE 2 DIABETES MELLITUS IN MEXICO: SIMULATION ANALYSIS, A PHARMACOECONOMIC PERSPECTIVE
|
Castañeda, RCL
|
|
2007
|
10 |
Supplement 2 |
p. A266-
1 p.
|
artikel
|
| 118 |
PDB28 IMPACT OF INITIATING OR CONVERTING TO TREATMENT WITH AN INSULIN ASPART ANALOG PEN ON MEDICATION ADHERENCE IN TYPE 2 DIABETES PATIENTS ON VIAL/SYRINGE INSULIN
|
Balu, S
|
|
2007
|
10 |
Supplement 2 |
p. A68-
1 p.
|
artikel
|
| 119 |
PDB23 IMPACT OF PATIENT EDUCATION ON HBA1C REDUCTION IN DIABETIC PATIENTS WITH CONCOMITANT HYPERTENSION
|
Shaya, FT
|
|
2007
|
10 |
Supplement 2 |
p. A66-
1 p.
|
artikel
|
| 120 |
PDB55 IMPACT ON HEALTH CARE COST OF INCREASING BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES—A CROSS SECTIONAL STUDY IN UNITED STATES
|
Colclough, HA
|
|
2007
|
10 |
Supplement 2 |
p. A271-
1 p.
|
artikel
|
| 121 |
PDB9 INDIRECT COMPARISON OF ONCE DAILY INSULIN DETEMIR AND GLARGINE IN REDUCING WEIGHT GAIN AND ACHIEVING GLYCEMIC CONTROL, WHEN ADMINISTERED IN ADDITION TO CONVENTIONAL ORAL ANTIDIABETIC THERAPY IN THE TREATMENT OFTYPE 2 DIABETES PATIENTS; A META-ANALYSIS
|
Fakhoury, W
|
|
2007
|
10 |
Supplement 2 |
p. A256-
1 p.
|
artikel
|
| 122 |
PDB22 INFLUENCE OF HEMOGLOBIN A1C TEST RESULT ON DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE 2 DIABETES
|
Durden, ED
|
|
2007
|
10 |
Supplement 2 |
p. A66-
1 p.
|
artikel
|
| 123 |
PDB41 INSULIN AND INSULIN ANCILLARY USAGE, THE ANNUAL COST OF TREATING TYPE 2 DIABETES WITH INSULIN IN THE UNITED KINGDOM
|
Chandler, F
|
|
2007
|
10 |
Supplement 2 |
p. A266-A267
nvt p.
|
artikel
|
| 124 |
PDB36 INSULIN USE AND COSTS OF CARDIOVASCULAR DISEASE EVENTS (CVD) AMONG PATIENTS WITH TYPE 2 DIABETES
|
Engel-Nitz, NM
|
|
2007
|
10 |
Supplement 2 |
p. A265-
1 p.
|
artikel
|
| 125 |
PDB68 ISA MEASUREMENT-GUIDED INTERVENTION PROGRAM TO LENGTHEN PERSISTENCE WITH METFORMIN MONOTHERAPY COST EFFECTIVE IN TYPE 2 DIABETES?
|
Kristanto, P
|
|
2007
|
10 |
Supplement 2 |
p. A275-
1 p.
|
artikel
|
| 126 |
PDB34 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF A MODERN INSULIN IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES IN THE GERMAN SETTING; DATA FROMTHE PREDICTIVE STUDY
|
Palmer, JL
|
|
2007
|
10 |
Supplement 2 |
p. A264-
1 p.
|
artikel
|
| 127 |
PDB47 LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH INSULIN ASPART VERSUS HUMAN BOLUS INSULIN IN TYPE 2 DIABETES PATIENTS IN THE SWEDISH SETTING
|
Valentine, WJ
|
|
2007
|
10 |
Supplement 2 |
p. A268-A269
nvt p.
|
artikel
|
| 128 |
PDB15 LOWER RATE OF HOSPITALIZATION IN SUBSEQUENTYEAR OF INSULIN GLARGINE VS NPH INITIATION IN INDIVIDUALS WITHTYPE 2 DIABETES (T2DM)
|
Leahy, J
|
|
2007
|
10 |
Supplement 2 |
p. A258-
1 p.
|
artikel
|
| 129 |
PDB37 MEALTIME INSULIN ASPART REDUCES THE LONG-TERM COST OF COMPLICATIONS COMPARED TO HUMAN INSULIN AS PART OF BASAL-BOLUS THERAPY IN POLISH TYPE 2 DIABETES PATIENTS
|
Goodall, G
|
|
2007
|
10 |
Supplement 2 |
p. A265-
1 p.
|
artikel
|
| 130 |
PDB59 METHODOLOGICAL APPROACH ASSESSING AN ASSOCIATION OF THE SURROGATE PARAMETER BETA-CELL ACTIVITY AND PATIENT-RELEVANT OUTCOMES IN TYPE 2 DIABETIC PATIENTS
|
Ulle, T
|
|
2007
|
10 |
Supplement 2 |
p. A272-
1 p.
|
artikel
|
| 131 |
PDB24 PRELIMINARY VALIDATION OF THE COGNITIVE DISTRESS, FATIGUE, HYPERGLYCEMIA AND HYPOGLYCEMIA SUBSCALES OF THE DIABETES SYMPTOM CHECKLIST REVISED (DCSR) FOR USE IN CLINICAL TRIALS INVOLVING PATIENTS WITH TYPE 1 OR TYPE 2 DIABETES
|
Kelly, AA
|
|
2007
|
10 |
Supplement 2 |
p. A66-A67
nvt p.
|
artikel
|
| 132 |
PDB6 RACIAL DIFFERENCES IN HOSPITALIZATIONS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES
|
Shenolikar, R
|
|
2007
|
10 |
Supplement 2 |
p. A60-A61
nvt p.
|
artikel
|
| 133 |
PDB12 ROSIGLITAZONE IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES: IMPLEMENTATION OF BUDGET IMPACT ANALYSIS SOFTWARE
|
Zaniolo, O
|
|
2007
|
10 |
Supplement 2 |
p. A257-
1 p.
|
artikel
|
| 134 |
PDB18 THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE:AN ECONOMIC EVALUATION PROJECTING RESULTS FROM A CLINICAL STUDY INTOTHE FUTURE USING AVALID AND RELIABLE ECONOMIC MODEL FROM ATHIRD PARTY PAYER PERSPECTIVE IN THE USA
|
Minshall, M
|
|
2007
|
10 |
Supplement 2 |
p. A259-
1 p.
|
artikel
|
| 135 |
PDB65 THE PROSIT DISEASE MODELLING COMMUNITY—OPEN SOURCE DEVELOPMENT OF DECISION ANALYTIC DISEASE MODELS FOR TYPE 2 DIABETES
|
Schramm, W
|
|
2007
|
10 |
Supplement 2 |
p. A274-
1 p.
|
artikel
|
| 136 |
PDB18 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
McEwan, P
|
|
2007
|
10 |
Supplement 2 |
p. A64-A65
nvt p.
|
artikel
|
| 137 |
PDB31 TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES
|
Baran, RW
|
|
2007
|
10 |
Supplement 2 |
p. A263-
1 p.
|
artikel
|
| 138 |
PDB76 TREATMENT SATISFACTION IS POSITIVELY ASSOCIATED WITH GLYCEMIC CONTROLAND NEGATIVELY ASSOCIATED WITH PATIENT REPORTED EXPERIENCE OF HYPOGLYCEMIC SYMPTOMS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE
|
Alvarez-Guisasola, F
|
|
2007
|
10 |
Supplement 2 |
p. A278-
1 p.
|
artikel
|
| 139 |
PDB50 UTILIZING OF CLAIMS DATABASES FOR IMPROVEMENT OF PRESCRIPTION HABITS FOR DIABETES MELLITUSTYPE 2
|
Ilavska, A
|
|
2007
|
10 |
Supplement 2 |
p. A269-A270
nvt p.
|
artikel
|
| 140 |
PDB14 2-YEAR GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE VERSUS NPH INSULIN IN INDIVIDUALS WITHTYPE 2 DIABETES (T2DM)
|
Leahy, J
|
|
2007
|
10 |
Supplement 2 |
p. A257-A258
nvt p.
|
artikel
|
| 141 |
PEN1 ESTIMATING THE QALY BENEFITS OF TREATMENT FOR GROWTH HORMONE DEFICIENCY (GHD) IN ADULT PATIENTS:A PRECURSOR TO COST-EFFECTIVENESS ANALYSIS
|
Koltowska-Haggstrom, M
|
|
2007
|
10 |
Supplement 2 |
p. A71-
1 p.
|
artikel
|
| 142 |
PEY13 ADJUNCTIVE THERAPY USE BY GLAUCOMA PATIENTS ON ORAL ANTIHYPERTENSIVES
|
Iskedjian, M
|
|
2007
|
10 |
Supplement 2 |
p. A145-
1 p.
|
artikel
|
| 143 |
PEY4 COST-EFFECTIVENESS ANALYSIS OF FIXED COMBINATION THERAPIES GANFORT, DUOTRAV AND XALACOM IN EUROPEAN COUNTRIES
|
Hommer, AB
|
|
2007
|
10 |
Supplement 2 |
p. A347-A348
nvt p.
|
artikel
|
| 144 |
PEY10 COST OF BLINDNESS IN THE CZECH REPUBLIC
|
Hájek, P
|
|
2007
|
10 |
Supplement 2 |
p. A144-
1 p.
|
artikel
|
| 145 |
PEY8 EFFECTIVENESS AND COSTS OF BETA-BLOCKERS WITH CAI OR ALPHA-2 FOLLOWING GLAUCOMA TREATMENT FAILURE: AN ANALYSIS CONDUCTED ON THE UK GENERAL PRACTITIONER RESEARCH DATABASE
|
Berdeaux, G
|
|
2007
|
10 |
Supplement 2 |
p. A143-A144
nvt p.
|
artikel
|
| 146 |
PEY7 EFFECTIVENESS AND COSTS OF PROSTAGLANDINS, WITH CAI OR AN ALPHA-2 AGONIST, IN THE TREATMENT OF GLAUCOMA:ANALYSIS CONDUCTED ON THE UK GENERAL PRACTITIONER RESEARCH DATABASE
|
Berdeaux, G
|
|
2007
|
10 |
Supplement 2 |
p. A143-
1 p.
|
artikel
|
| 147 |
PG15 EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS: A DECISION-ANALYTIC MODEL
|
Nielsen, SK
|
|
2007
|
10 |
Supplement 2 |
p. A353-
1 p.
|
artikel
|
| 148 |
PGI12 HAVING YOUR CAKE AND EATING IT TOO: RESULTS FROM A POLICY ANALYSIS OF A PROTON PUMP INHIBITOR PREFERRED DRUG LIST
|
Martin, BC
|
|
2007
|
10 |
Supplement 2 |
p. A150-
1 p.
|
artikel
|
| 149 |
PGI20 MAINTENANCE THERAPY WITH INFLIXIMAB REDUCES HOSPITALIZARON AND SURGERY IN CROHN'S DISEASE
|
Thompson, HC
|
|
2007
|
10 |
Supplement 2 |
p. A357-A358
nvt p.
|
artikel
|
| 150 |
PGI23 USING DISCRETE CHOICE EXPERIMENTS (DCE)TO MEASURE PREFERENCES FOR TREATMENT OPTIONS: AN APPLICATION TO GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
|
Kilonzo, MM
|
|
2007
|
10 |
Supplement 2 |
p. A358-
1 p.
|
artikel
|
| 151 |
PHM5 ADVATE IS COST-EFFECTIVE INVESTMENT IN HEMOPHILIA A TREATMENT WHEN PATHOGENS EMERGE—A SCENARIO-BASED ECONOMIC AND POSITIVE INVESTMENT INTERVAL (Pll) EVALUATION
|
Soini, EJ
|
|
2007
|
10 |
Supplement 2 |
p. A281-
1 p.
|
artikel
|
| 152 |
PHM2 BUDGET IMPACT (Bl) OF PARENTERAL IRON TREATMENT OF IRON DEFICIENCY ANAEMIA (IDA) IN SWITZERLAND
|
Steiner, S
|
|
2007
|
10 |
Supplement 2 |
p. A280-
1 p.
|
artikel
|
| 153 |
PHM9 THE ASSOCIATION OF BARRIERS TO CARE AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH FACTOR VIII DEFICIENCY-THE HEMOPHILIA UTILIZATION GROUP STUDYPART V (HUGS-V)
|
Wu, J
|
|
2007
|
10 |
Supplement 2 |
p. A155-
1 p.
|
artikel
|
| 154 |
PHM19 USING THE EQ-5DTO MONITOR HEALTH-RELATED QUALITY OF LIFE OVERTIME IN THE CATALAN HEALTH INTERVIEW SURVEY
|
Herdman, M
|
|
2007
|
10 |
Supplement 2 |
p. A285-
1 p.
|
artikel
|
| 155 |
PHP23 A NATIONAL SURVEY ON PRESCRIBERS' KNOWLEDGE OF AND THEIR SOURCE OF DRUG-DRUG INTERACTION INFORMATION
|
Ko, Y
|
|
2007
|
10 |
Supplement 2 |
p. A28-A29
nvt p.
|
artikel
|
| 156 |
PHP6 CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE USE AND OUT-OF-POCKET PRESCRIPTION COSTS
|
Alexander, GC
|
|
2007
|
10 |
Supplement 2 |
p. A23-
1 p.
|
artikel
|
| 157 |
PHP20 IMPACT OF POLYPHARMACY MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) ON DRUG EXPENDITURES IN MEDICARE PART D POPULATION
|
Miller, SA
|
|
2007
|
10 |
Supplement 2 |
p. A28-
1 p.
|
artikel
|
| 158 |
PHP35 PROFILE OF PHYSICIANS' PRESCRIPTION IN GREECE
|
Tsiantou, V
|
|
2007
|
10 |
Supplement 2 |
p. A371-
1 p.
|
artikel
|
| 159 |
PHP8 THE CHALLENGE OF A LEGITIMATE BUDGET IMPACT RATIONING CRITERION IN DRUG REIMBURSEMENT DECISIONS
|
Niezen, MGH
|
|
2007
|
10 |
Supplement 2 |
p. A363-
1 p.
|
artikel
|
| 160 |
PHP37 THE MARKET SHARE OF PRIVATE FOR-PROFIT AND NONPROFIT HEALTH CARE PROVIDERS FROM THE HUNGARIAN HEALTH INSURANCE BUDGET
|
Boncz, I
|
|
2007
|
10 |
Supplement 2 |
p. A33-
1 p.
|
artikel
|
| 161 |
PIH10 AN ECONOMIC ASSESSMENT OF THE CONTENT OF HOME PHARMACIES AND SELF MEDICATION PRACTICE AMONG FAMILIES IN SLOVAK REPUBLIC AND SERBIA CITIES
|
Sabo, A
|
|
2007
|
10 |
Supplement 2 |
p. A375-A376
nvt p.
|
artikel
|
| 162 |
PIH3 COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL CONTRACEPTIVE METHODS
|
Gajria, KL
|
|
2007
|
10 |
Supplement 2 |
p. A156-
1 p.
|
artikel
|
| 163 |
PIH13 FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING FOR BREAST CANCER
|
Zammit, DC
|
|
2007
|
10 |
Supplement 2 |
p. A376-A377
nvt p.
|
artikel
|
| 164 |
PIN46 A CROSS-SECTIONAL VALIDATION OF THE MINI-HIV QUESTIONNAIRE
|
Pedrol, E
|
|
2007
|
10 |
Supplement 2 |
p. A450-
1 p.
|
artikel
|
| 165 |
PIN29 AZITHROMYCIN PLUS CEFTRIAXONE VERSUS LEVOFLOXACIN IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN SPAIN. A COST-MINIMIZATION ANALYSIS
|
Barbera, J
|
|
2007
|
10 |
Supplement 2 |
p. A444-
1 p.
|
artikel
|
| 166 |
PIN5 CLINICAL AND ECONOMIC OUTCOMES OF VANCOMYCIN FOR GRAM-POSITIVE INFECTIONS IN AN ERA OF INCREASING RESISTANCE:A SYSTEMATIC REVIEW
|
Stephens, JM
|
|
2007
|
10 |
Supplement 2 |
p. A160-A161
nvt p.
|
artikel
|
| 167 |
PIN15 COST-EFFECTIVENESS OF AUGMENTIN ES® FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND
|
Kawalec, P
|
|
2007
|
10 |
Supplement 2 |
p. A440-
1 p.
|
artikel
|
| 168 |
PIN12 COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN COMPLICATED SKIN AND SOFT-TISSUE INFECTION DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE
|
De Cock, E
|
|
2007
|
10 |
Supplement 2 |
p. A439-
1 p.
|
artikel
|
| 169 |
PIN11 COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPES 2 AND 3 IN BRAZIL
|
Parana, R
|
|
2007
|
10 |
Supplement 2 |
p. A438-A439
nvt p.
|
artikel
|
| 170 |
PIN22 IMPACT OF S.AUREUS INFECTIONS ON EXPENDITURES AND LENGTH-OF-STAY IN U.S. HOSPITALS
|
Noskin, G
|
|
2007
|
10 |
Supplement 2 |
p. A166-
1 p.
|
artikel
|
| 171 |
PIN37 LESSONS LEARNED IN EVALUATING THE IMPACT OF VACCINES ON HEALTH CARE UTILIZATION IN TWO LARGE RANDOMIZED CLINICAL TRIALS
|
Itzler, R
|
|
2007
|
10 |
Supplement 2 |
p. A170-
1 p.
|
artikel
|
| 172 |
PMC34 AN APPLICATION OF ITEM RESPONSE THEORY TO PRESCRIBERS' KNOWLEDGE AND ATTITUDE MEASUREMENT
|
Ko, Y
|
|
2007
|
10 |
Supplement 2 |
p. A193-A194
nvt p.
|
artikel
|
| 173 |
PMC30 ECONOMIC ADVANTAGES OF ONLINE DISCRETE EVENT SIMULATION TRAINING
|
Hunting, B
|
|
2007
|
10 |
Supplement 2 |
p. A459-A460
nvt p.
|
artikel
|
| 174 |
PMC13 NONLINEAR SMOOTHING TO ASSESS PROBABILITIES OF ANTIBIOTIC-RESISTANT INFECTIONS IN THE COMUNITAT VALENCIANA (SPAIN)
|
Armero, C
|
|
2007
|
10 |
Supplement 2 |
p. A454-
1 p.
|
artikel
|
| 175 |
PMC17 PRINCIPAL COMPONENT ANALYSIS OF A PATIENT SATISFACTION OF CARE SURVEY AND THE RELATIONSHIP BETWEEN PRINCIPAL COMPONENTS AND OVERALL SATISFACTION
|
Livengood, K
|
|
2007
|
10 |
Supplement 2 |
p. A188-
1 p.
|
artikel
|
| 176 |
PMC31 PROPOSAL FOR A METHODOLOGICAL CHANGE OF PRACTISE: SEPARATING THE PROCESS OF ESTIMATING CLINICAL EFFECTIVENESS FROM ECONOMIC EVALUATIONS
|
Waechter, F
|
|
2007
|
10 |
Supplement 2 |
p. A192-A193
nvt p.
|
artikel
|
| 177 |
PMC16 SF-6D REFERENCE VALUES FOR SPANISH GENERAL POPULATION
|
Moris, J
|
|
2007
|
10 |
Supplement 2 |
p. A455-
1 p.
|
artikel
|
| 178 |
PMC2 THE EFFECT OF PHARMACIST CONSULTATION ON PATIENT MEDICATION ADHERENCE:AN INSTRUMENTAL VARIABLE APPROACH
|
Gu, NY
|
|
2007
|
10 |
Supplement 2 |
p. A184-
1 p.
|
artikel
|
| 179 |
PMH19 A COMPARISON OF TOTAL DIRECT MEDICAL COSTS TO MANAGED CARE OF ESCITALOPRAM VERSUS VENLAFAXINE XR TREATMENT IN MAJOR DEPRESSIVE DISORDER
|
Erder, MH
|
|
2007
|
10 |
Supplement 2 |
p. A77-
1 p.
|
artikel
|
| 180 |
PMH27 COST-EFFECTIVENESS OF DULOXETINE VS. VENLAFAXINE XRAND SSRIS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN PRIMARY AND SECONDARY CARE IN SPAIN
|
De Cock, E
|
|
2007
|
10 |
Supplement 2 |
p. A295-A296
nvt p.
|
artikel
|
| 181 |
PMH30 DIRECT COSTS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE
|
Luppa, M
|
|
2007
|
10 |
Supplement 2 |
p. A296-
1 p.
|
artikel
|
| 182 |
PMH13 IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): 18 MONTH INTERIM RESULTS FROM BELGIAN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)
|
Peuskens, J
|
|
2007
|
10 |
Supplement 2 |
p. A291-
1 p.
|
artikel
|
| 183 |
PMH34 PHARMACOLOGIC TREATMENT OF GENERALIZED ANXIETY DISORDER WITH COMORBID DEPRESSION AND PAIN CONDITIONS
|
Ye, W
|
|
2007
|
10 |
Supplement 2 |
p. A81-
1 p.
|
artikel
|
| 184 |
PMH16 PREDICTORS OF HIGH COSTS FOR GENERALIZED ANXIETY DISORDER WITH OR WITHOUT PAIN
|
Zhu, B
|
|
2007
|
10 |
Supplement 2 |
p. A76-
1 p.
|
artikel
|
| 185 |
PMH48 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF ATOMOXETINE USING DISCRETE CHOICE ANALYSIS: UK PARENTS PERSPECTIVE
|
Cottrell, S
|
|
2007
|
10 |
Supplement 2 |
p. A86-
1 p.
|
artikel
|
| 186 |
PMH54 PRELIMINARY VALIDATION OF THE ENGLISH VERSION OF THE SCHIZOPHRENIA QUALITY OF LIFE (S-QOL) SCALE
|
Auquier, P
|
|
2007
|
10 |
Supplement 2 |
p. A304-
1 p.
|
artikel
|
| 187 |
PND23 A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH GLATIRAMER ACETATE INJECTION OR HIGH-DOSE INTERFERON BETA-IA
|
Castelli-Haley, J
|
|
2007
|
10 |
Supplement 2 |
p. A387-
1 p.
|
artikel
|
| 188 |
PND10 AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY BURDEN OF INSOMNIA AND ITS TREATMENT
|
Hawkins, K
|
|
2007
|
10 |
Supplement 2 |
p. A89-
1 p.
|
artikel
|
| 189 |
PND37 A REVIEW OF PATIENT-REPORTED OUTCOMES THAT COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN ADULT EPILEPSY DRUG TRIALS
|
Hoffman, PL
|
|
2007
|
10 |
Supplement 2 |
p. A391-A392
nvt p.
|
artikel
|
| 190 |
PND6 COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE PRESENCE OF LONG-TERM CLINICAL EVIDENCE
|
Graham, JB
|
|
2007
|
10 |
Supplement 2 |
p. A381-
1 p.
|
artikel
|
| 191 |
PND20 COST-UTILITY ANALYSIS EVALUATING THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY
|
Liedgens, H
|
|
2007
|
10 |
Supplement 2 |
p. A386-
1 p.
|
artikel
|
| 192 |
PND27 DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8
|
Luo, N
|
|
2007
|
10 |
Supplement 2 |
p. A94-A95
nvt p.
|
artikel
|
| 193 |
PND13 HEALTH CARE COSTS AND UTILIZATION FOR ALZHEIMER'S DISEASE PATIENTS
|
Zhao, Y
|
|
2007
|
10 |
Supplement 2 |
p. A90-
1 p.
|
artikel
|
| 194 |
POI3 A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN SWEDEN AND DENMARK
|
Chhabra, A
|
|
2007
|
10 |
Supplement 2 |
p. A97-
1 p.
|
artikel
|
| 195 |
POS14 COMPARISON OF SF-6DAND EQ-5D UTILITIES IN OSTEOPOROTIC HIP FRACTURE PATIENTS
|
Golicki, D
|
|
2007
|
10 |
Supplement 2 |
p. A397-A398
nvt p.
|
artikel
|
| 196 |
POS11 FALL-RELATED HOSPITALIZATION AND FACILITY COSTS AMONG RESIDENTS RECEIVING LONG-TERM CARE
|
Carroll, NV
|
|
2007
|
10 |
Supplement 2 |
p. A396-A397
nvt p.
|
artikel
|
| 197 |
PPN3 EXPECTED COST AND COST CONSIDERATIONS ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC NON-CANCER PAIN: A SIMULATION MODEL
|
Magar, RS
|
|
2007
|
10 |
Supplement 2 |
p. A464-
1 p.
|
artikel
|
| 198 |
PPN16 PRESCRIBING OF FENTANYL PATCHES TO NON-OPIOID TOLERANT PATIENTS IN THE MILITARY HEALTH SYSTEM (MHS)
|
Trice, S
|
|
2007
|
10 |
Supplement 2 |
p. A176-
1 p.
|
artikel
|
| 199 |
PPN1 SURVEY OF CHRONIC PAIN IN TURKEY
|
Tulunay, FC
|
|
2007
|
10 |
Supplement 2 |
p. A171-
1 p.
|
artikel
|
| 200 |
Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited
|
Hollenbeak, Christopher S.
|
|
2007
|
10 |
Supplement 2 |
p. S4-S11
8 p.
|
artikel
|
| 201 |
Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited
|
Hollenbeak, Christopher S.
|
|
2007
|
10 |
Supplement 2 |
p. S4-S11
|
artikel
|
| 202 |
PR6 PATIENT CHARACTERISTICS IMPACTING QUALITY OF LIFE (EQ-5D) OF FEMALES WITH STRESS URINARY INCONTINENCE SYMPTOMS
|
Tincello, D
|
|
2007
|
10 |
Supplement 2 |
p. A229-
1 p.
|
artikel
|
| 203 |
PR2 PREDICTING DISEASE BURDEN IN EQ-5D US UNITS FROM SEVEN OTHER MEASUREMENT SYSTEMS (EQ-5D UK, HALEX, HUI MARK 2, HUI MARK 3, QWB-SA, SF-6D(12), SF-6D(36))
|
Hanmer, J
|
|
2007
|
10 |
Supplement 2 |
p. A15-A16
nvt p.
|
artikel
|
| 204 |
PRS11 MARKOV MODEL FOR COPD: COMPARING TREEAGE AND ARENA SOFTWARE AND VALIDATING THE MODEL
|
Menn, P
|
|
2007
|
10 |
Supplement 2 |
p. A310-
1 p.
|
artikel
|
| 205 |
PRS11 PERCEPTIONS ABOUT BEHIND-THE-COUNTER AVAILABILITY OF PSEUDOEPHEDRINE
|
Shi, CW
|
|
2007
|
10 |
Supplement 2 |
p. A180-
1 p.
|
artikel
|
| 206 |
PRS8 S-MEDDIAL PROJECT OF COOPERATION WITH PEDIATRICIANS ON PROVIDING INDIVIDUAL FEEDBACK ON ANTIBIOTICS PRESCRIPTION IN ORDERTO IMPROVE PRESCRIPTION HABITS AND TO RATIONALIZE DRUG SPENDING
|
Hupkova, H
|
|
2007
|
10 |
Supplement 2 |
p. A309-
1 p.
|
artikel
|
| 207 |
PSK1 IMPACT OF SECONDARY PROPHYLACTIC USE OF TACROLIMUS 0.1% OINTMENT ON QUALITY-OF-LIFE, TREATMENT OUTCOMES AND COSTS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
|
Wollenberg, A
|
|
2007
|
10 |
Supplement 2 |
p. A467-A468
nvt p.
|
artikel
|
| 208 |
PSK5 MANAGEMENT AND COST OF GENITAL WARTS IN ITALY
|
Mérito, M
|
|
2007
|
10 |
Supplement 2 |
p. A469-
1 p.
|
artikel
|
| 209 |
PSK6 THE IMPACT OF PSORIASIS ON HEALTH CARE COSTS AND WORK LOSS
|
Duh, MS
|
|
2007
|
10 |
Supplement 2 |
p. A100-A101
nvt p.
|
artikel
|
| 210 |
PSM6 REAL WORLD USAGE PATTERNS OF OVER-THE-COUNTER NICOTINE PATCHES
|
Shi, CW
|
|
2007
|
10 |
Supplement 2 |
p. A473-
1 p.
|
artikel
|
| 211 |
PST2 HOSPITAL-BASED OUTCOMES ASSOCIATED WITH NONTRAUMATIC SUBARACHNOID HEMORRHAGE
|
Van Den Bos, J
|
|
2007
|
10 |
Supplement 2 |
p. A181-
1 p.
|
artikel
|
| 212 |
PSU2 COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN SWEDEN AND DENMARK
|
Alt, V
|
|
2007
|
10 |
Supplement 2 |
p. A183-
1 p.
|
artikel
|
| 213 |
PSU3 SAVINGS OF THE USE OF RHBMP-2 IN OPEN TIBIA FRACTURES FOR EUROPEAN HEALTH CARE SYSTEMS FROM A PAYER AND SOCIETAL PERSPECTIVE
|
Alt, V
|
|
2007
|
10 |
Supplement 2 |
p. A184-
1 p.
|
artikel
|
| 214 |
PUK10 COST ANALYSIS OF PRE-DIALYSIS CHRONIC KIDNEY DISEASE:AN EMPLOYER'S PERSPECTIVE
|
Moyneur, É
|
|
2007
|
10 |
Supplement 2 |
p. A105-
1 p.
|
artikel
|
| 215 |
PUK18 INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY
|
Boncz, I
|
|
2007
|
10 |
Supplement 2 |
p. A318-
1 p.
|
artikel
|
| 216 |
PUK4 IN THE UNITED KINGDOM, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED FOR RENAL REPLACEMENT THERAPY (RRT)
|
Sondhi, S
|
|
2007
|
10 |
Supplement 2 |
p. A314-
1 p.
|
artikel
|
| 217 |
PUK13 PANEL DATA ANALYSIS SHOWS PERITONEAL DIALYSIS TO BE NEGATIVELY ASSOCIATED WITH HOSPITALIZATION AT THE STATE LEVEL
|
Walker, DR
|
|
2007
|
10 |
Supplement 2 |
p. A106-
1 p.
|
artikel
|
| 218 |
PUK21 THE IMPACT OF ICODEXTRIN ON QUALITY OF LIFE IN DIABETIC PATIENTS ON PERITONEAL DIALYSIS OVERTIME: A REGRESSION ANALYSIS
|
Walker, PR
|
|
2007
|
10 |
Supplement 2 |
p. A319-
1 p.
|
artikel
|
| 219 |
Quality of Life Assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of Patients on Renal Replacement Therapy: A Systematic Review and Meta-Analysis
|
Liem, Ylian S.
|
|
2007
|
10 |
Supplement 2 |
p. 390-397
8 p.
|
artikel
|
| 220 |
Quality of Life Assessed with the Medical Outcomes Study Short Form 36-Item Health Survey of Patients on Renal Replacement Therapy: A Systematic Review and Meta-Analysis
|
Liem, Ylian S.
|
|
2007
|
10 |
Supplement 2 |
p. 390-397
|
artikel
|
| 221 |
RS1 COST EFFECTIVENESS OF QUANTIFERON IN SCREENING FOR TUBERCULOSIS INFECTION IN CLOSE CONTACTS IN JAPAN
|
Kowada, A
|
|
2007
|
10 |
Supplement 2 |
p. A10-
1 p.
|
artikel
|
| 222 |
SU1 COST-EFFECTIVENESS OF CYCLOOXYGENASE-2 INHIBITOR PARECOXIB COMPARED TO OPIOIDS AFTER NONCARDIAC SURGERY INTHE UNITED KINGDOM
|
Remák, E
|
|
2007
|
10 |
Supplement 2 |
p. A230-
1 p.
|
artikel
|
| 223 |
The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease
|
Brennan, Alan
|
|
2007
|
10 |
Supplement 2 |
p. 32-41
10 p.
|
artikel
|
| 224 |
The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease
|
Brennan, Alan
|
|
2007
|
10 |
Supplement 2 |
p. 32-41
|
artikel
|
| 225 |
The Mayo Clinic Manuscript Series Relative to the Discussion, Dissemination, and Operationalization of the Food and Drug Administration Guidance on Patient-Reported Outcomes
|
Sloan, Jeff A.
|
|
2007
|
10 |
Supplement 2 |
p. S59-S63
5 p.
|
artikel
|
| 226 |
The Mayo Clinic Manuscript Series Relative to the Discussion, Dissemination, and Operationalization of the Food and Drug Administration Guidance on Patient-Reported Outcomes
|
Sloan, Jeff A.
|
|
2007
|
10 |
Supplement 2 |
p. S59-S63
|
artikel
|
| 227 |
The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan
|
Tsai, Yi-Wen
|
|
2007
|
10 |
Supplement 2 |
p. 117-127
11 p.
|
artikel
|
| 228 |
The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan
|
Tsai, Yi-Wen
|
|
2007
|
10 |
Supplement 2 |
p. 117-127
|
artikel
|
| 229 |
Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report
|
Garrison Jr., Louis P.
|
|
2007
|
10 |
Supplement 2 |
p. 326-335
10 p.
|
artikel
|
| 230 |
Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report
|
Garrison, Louis P.
|
|
2007
|
10 |
Supplement 2 |
p. 326-335
|
artikel
|
Tijdschrift beschrijving